Answers are grounded in this paper and cite their sources.
Development of a preventive immunogen for human immunodeficiency virus (HIV) infection is a national priority. The complexities associated with HIV host-virus interactions, coupled with the rapid progression of the HIV epidemic worldwide, have necessitated lowering expectations for an HIV vaccine that is 100 percent effective and have raised important scientific and nonscientific issues regarding development and use of preventive and therapeutic HIV vaccines.
No takes yet. Share an insight, caveat, or question.
Barton F. Haynes (1993) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: